Characterizing biological products and assessing comparability following manufacturing changes

被引:270
作者
Chirino, AJ
Mire-Sluis, A
机构
[1] Xencor Inc, Monrovia, CA 91016 USA
[2] Ctr Drug Evaluat & Res, Off Pharmaceut Sci, Rockville, MD 20852 USA
关键词
D O I
10.1038/nbt1030
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Changes in production methods of a biological product may necessitate an assessment of comparability to ensure that these manufacturing changes have not affected the safety, identity, purity, or efficacy of the product. Depending on the nature of the protein or the change, this assessment consists of a hierarchy of sequential tests in analytical testing, preclinical animal studies and clinical studies. Differences in analytical test results between pre- and post-change products may require functional testing to establish the biological or clinical significance of the observed difference. An underlying principle of comparability is that under certain conditions, protein products may be considered comparable on the basis of analytical testing results alone. However, the ability to compare biological materials is solely dependent on the tests used, since no single analytical method is able to compare every aspect of protein structure or function. The advantages and disadvantages of any given method depends on the protein property being characterized.
引用
收藏
页码:1383 / 1391
页数:9
相关论文
共 92 条
  • [1] ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582
  • [2] M-07E HUMAN LEUKEMIC FACTOR-DEPENDENT CELL-LINE PROVIDES A RAPID AND SENSITIVE BIOASSAY FOR THE HUMAN CYTOKINES GM-CSF AND IL-3
    AVANZI, GC
    BRIZZI, MF
    GIANNOTTI, J
    CIARLETTA, A
    YANG, YC
    PEGORARO, L
    CLARK, SC
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1990, 145 (03) : 458 - 464
  • [3] Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C
    Bailon, P
    Palleroni, A
    Schaffer, CA
    Spence, CL
    Fung, WJ
    Porter, JE
    Ehrlich, GK
    Pan, W
    Xu, ZX
    Modi, MW
    Farid, A
    Berthold, W
    [J]. BIOCONJUGATE CHEMISTRY, 2001, 12 (02) : 195 - 202
  • [4] BARBOSA MDF, 2003, 90 M AM SOC IMM AM S
  • [5] Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory
    Bertolotto, A
    Malucchi, S
    Sala, A
    Orefice, G
    Carrieri, PB
    Capobianco, M
    Milano, E
    Melis, F
    Giordana, MT
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (02) : 148 - 153
  • [6] Interferon β neutralizing antibodies in multiple sclerosis:: neutralizing activity and cross-reactivity with three different preparations
    Bertolotto, A
    Malucchi, S
    Milano, E
    Castello, A
    Capobianco, M
    Mutani, R
    [J]. IMMUNOPHARMACOLOGY, 2000, 48 (02): : 95 - 100
  • [7] Evaluation of genetic stability of recombinant human factor VIII by peptide mapping and on-line mass spectrometric analysis
    Besman, MJ
    Shiba, D
    [J]. PHARMACEUTICAL RESEARCH, 1997, 14 (08) : 1092 - 1098
  • [8] Bohidar HB, 1998, BIOPOLYMERS, V45, P1
  • [9] The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H
    Boyd, PN
    Lines, AC
    Patel, AK
    [J]. MOLECULAR IMMUNOLOGY, 1995, 32 (17-18) : 1311 - 1318
  • [10] Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice
    Braun, A
    Kwee, L
    Labow, MA
    Alsenz, J
    [J]. PHARMACEUTICAL RESEARCH, 1997, 14 (10) : 1472 - 1478